Review

Comprehensive review of reports of menstrual irregularities associated with isotretinoin

Priya Chelliah BA *, Donald Glass MD, PhD

University of Texas Southwestern Medical Center, Dallas, TX, United States

ABSTRACT

In 1982, oral isotretinoin was first licensed as a treatment option for severe recalcitrant cystic acne in the United States. Since its introduction into the pharmaceutical market, several instances of amenorrhea in women of child-bearing age taking isotretinoin have been reported. In each documented instance, amenorrhea spontaneously resolved once the medication was discontinued. The Patient Introductory Brochure for iPLEDGE, the risk management distribution program mandated by the U.S. Food and Drug Administration for isotretinoin, does not currently include menstrual irregularities as a side effect of treatment; thus, patients who experience this side effect may also experience the unnecessary stress of a possible pregnancy, or, if a minor, explaining a lack of menses to their parent/guardian. This review synthesizes the limited literature available on this subject to advocate for more widespread acknowledgment of menstrual irregularities as a side effect of isotretinoin therapy. To perform the literature review, the search was conducted on June 13, 2020 on PubMed using the following search terms: (((isotretinoin) AND (oligomenorrhea))) OR ((isotretinoin) AND (amenorrhea)) OR ((isotretinoin) AND (PCOS)) OR ((isotretinoin) AND (menstrual irregularities)) OR ((isotretinoin) AND (polycystic ovary syndrome)). All years available were included. Articles were excluded if they were not published in English or did not address the topic of menstrual irregularities in the setting of isotretinoin, with or without the presence of polycystic ovary syndrome. A total of six articles met our criteria and are described.

© 2020 Published by Elsevier Inc. on behalf of Women’s Dermatologic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

In 1982, oral isotretinoin was first licensed as a treatment option for severe recalcitrant cystic acne in the United States (McElwee et al., 1991). Since its introduction into the pharmaceuti-
experience the unnecessary stress of a possible pregnancy, or, if a minor, explaining a lack of menses to their parent/guardian. This review synthesizes the limited literature available on this subject to advocate for more widespread acknowledgment of menstrual irregularities as a side effect of isotretinoin therapy.

Methods

To perform the literature review, a search was conducted on June 13, 2020 on PubMed using the following search terms: (((isotretinoin) AND (oligomenorrhea)) OR ((isotretinoin) AND (amenorrhea)) OR ((isotretinoin) AND (PCOS)) OR ((isotretinoin) AND (menstrual irregularities)) OR ((isotretinoin) AND (polycystic ovary syndrome))). All years available were included. Articles were excluded if they were not published in English or did not address irregularities as a side effect of isotretinoin therapy.

Results

There are several case reports that document menstrual abnormalities associated with female patients who are not taking oral contraceptive pills (OCPs) to regulate their menstrual cycles. For instance, a 1988 case report by Cox (1988) described a 14-year-old girl who was 10 weeks into a course of isotretinoin when she reported that she had not menstruated during that time frame despite having regular menstruation for the 3 years prior. Ten days after stopping the medication, her menstruation resumed (Cox, 1988). Furthermore, in a 2016 trial of 50 patients started on isotretinoin for acne vulgaris, Saljoughi et al. (2017) reported that 34% of the female patients (53.9% male and 46.1% female) experienced increased liver enzymes and two female patients experienced amenorrhea. Another case study in 2007 demonstrated that a 17-year-old female patient who previously had menstrual cycles lasting 28 days with 5 days of bleeding experienced prolonged menstrual bleeding after initiating isotretinoin. She was taking an OCP. Her bleeding stopped 2 days after isotretinoin was discontinued, but she had another episode of prolonged bleeding after resuming isotretinoin at a later time (Christmas, 1988).

A retrospective chart review of 40 female patients taking isotretinoin found that 8 patients reported new menstrual irregularities. None of the patients were on OCPs, and they presented with normal levels of follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, and prolactin. All eight female patients resumed normal menstrual cycles after discontinuation of the drug. The authors concluded that in younger patients, normal menstrual cycles before and after administration of the drug was suspicious for involvement of isotretinoin in altering the menstrual cycles of the patients (Kwon et al., 2007). Despite the prevalence of amenorrhea in women on isotretinoin that has been demonstrated to stop and start with the use of the medication, it was not listed as a potential side effect of the medication during patient education prior to enrollment in iPLEDGE. Thus, menstrual side effects of the medication continue to cause anxiety and confusion within this population due to a lack of patient education.

The best practice guidelines for PCOS that state “girls with severe acne refractory to treatments including isotretinoin may have a 40% likelihood of developing PCOS” (Goodman et al., 2015). This has led to concern over the differentiation between PCOS and menstrual irregularities secondary to isotretinoin treatment. Although PCOS is clearly a confounding factor in evaluating menstrual irregularities, many of the papers evaluated demonstrated that irregularities began and stopped with isotretinoin treatment, leading authors to the conclusion that the effects may be directly related to isotretinoin (Kwon et al., 2007).

Conclusions

The iPLEDGE program is essential in avoiding major maternal-fetal complications associated with isotretinoin use while pregnant, but menstrual irregularities can cause unnecessary anxiety and stress for women taking isotretinoin who are not on OCPs. These women are simply unaware of or uneducated about this as a potential medication side effect. Despite the screening and reporting of other adverse effects with similar incidence rates, amenorrhea continues to be excluded from the list of potential side effects. As of June 2020, the Absorica highlights of prescription

### Table 1

| Characteristics of included journal articles. |
|-----------------------------------------------|
| No. of participants in study | No. with menstrual irregularities | PCOS evaluated? | First author, year |
|-------------------------------|-----------------------------------|-----------------|-------------------|
| 466                           | 2                                 | Not assessed    | McElwee et al., 1991 |
| 1                             | 1                                 | Not assessed    | Cox, 1988         |
| 5                             | 5                                 | Not assessed    | Christmas, 1988   |
| 40                            | 8                                 | Not assessed    | Kwon et al., 2007 |
| 50                            | 17                                | Confirmed: 10% had PCOS | Saljoughi et al., 2017 |
| N/A                           | N/A                               | Confirmed; best practice guidelines | Goodman et al., 2015 |

N/A, not applicable; PCOS, polycystic ovarian syndrome.

---

Fig. 1. PRISMA flow diagram.
Amnesteem package insert (updated 2019), and Myorisan package insert (updated 2018) include abnormal menses, but the iPLEGE booklet does not (iPLEGE, 2016). Thus, we argue that patient care can be improved by including amenorrhea in the list of potential side effects for women of childbearing potential who are planning to take isotretinoin.

References
Absorica (isotretinoin). Highlights of prescribing. Humacao, P. G. P. R., Inc.; 2019.
Amnesteem (isotretinoin). Package insert. Morgantown, W. M. P. I.; 2019.
Christmas T. Roaccutane and menorrhagia. J Am Acad Dermatol 1988;18(3):576–7.
Cox NH. Amenorrhea during treatment with isotretinoin. Br J Dermatol 1988;118 (6):857–8.
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—Part 1. Endocr Pract 2015;21(11):1291–300.
iPLEGE. Patient introductory brochure. iPLEGE; 2016.
Kwon HJ, Lee JY, Cho BK, Park HJ. Menstrual irregularity during isotretinoin treatment. J Eur Acad Dermatol Venereol 2007;21(4):562–3.
McElwee NE, Schumacher MC, Johnson SC, Weir TW, Greene SL, Scotvold MJ, et al. An observational study of isotretinoin recipients treated for acne in a health maintenance organization. Arch Dermatol 1991;127(3):341–6.
Myorisan (isotretinoin). Package insert. Lake Forest, I. A. P. I.; 2018.
Saljoughi N, Jebraihi R, Yasjani M, Tehrani S, Ghaedi F. The effects of oral isotretinoin on sex hormones and menstrual cycle in women with severe acne. J Dermatol Cosmet 2017;7(4):200–5.